Global Ticagrelor Market

Ticagrelor Comprehensive Study by Application (Acute Coronary Syndromes, Percutaneous Coronary Intervention, Others), Distribution Channel (Retail Pharmacies, Hospitals and Healthcare Facilities, Specialty Pharmacies, Others), End User (Hospitals, Ambulatory Surgical Centers, Pharmacies, Others) Players and Region - Global Market Outlook to 2030

Ticagrelor Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Ticagrelor
Ticagrelor is called an antiplatelet medicine. Ticagrelor is used for the prevention of blood clots and certain cardiovascular conditions. It is a PY212 receptor. It is an antiplatelet agent; the ticagrelors include cyclopentyl-triazolo-pyrimidine antiplatelet agents. The ticagrelor is allowing a quick return to normal function; it is an anticipated agent; it reduces the risk of major cardiovascular events, and it improves overall survival rates in patients. Ongoing research and development activities in the pharmaceutical industry contribute to the introduction of new and improved medications. If there are further advancements or new developments in ticagrelor, it may be driving market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the stiff market share occupied by leading players. The companies are implementing strategic activities such as acquisition and mergers along with collaboration with companies in other industries to help them in improving sustenance and maintaining their competitive advantages. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), Pfizer Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Boehringer Ingelheim International GmbH. (Germany), Maithili Life Sciences Pvt. Ltd (India), Teva Pharmaceutical Industries (Israel), Dr. Reddy’s Laboratories Ltd. (India), Hisun Pharm Hangzhou (China), Aarti Pharmalabs Limited (India), Bristol-Myers Squibb Company (United States), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Cipla Limited (India) and Janssen Pharmaceuticals, Inc (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Ticagrelor market by , Application (Acute Coronary Syndromes, Percutaneous Coronary Intervention and Others) and Region.



On the basis of geography, the market of Ticagrelor has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Retail Pharmacies will boost the Ticagrelor market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Ticagrelor market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
The increasing prevalence of cardiovascular diseases, such as coronary artery disease and acute coronary syndrome and The growing awareness of the benefits of ticagrelor in preventing heart attack and stroke

Challenges:
Ticagrelor is a relatively expensive medication and Ticagrelor faces competition from other antiplatelet medications.

Restraints:
Stringent regulatory processes and approvals can slow down the entry of ticagrelor into new markets and Limited Indications of ticagrelor medicines

Opportunities:
Focus on ongoing research and discovers new therapeutic indications for ticagrelor. and Incorporating digital health solutions for better patient management and adherence

Market Leaders and their expansionary development strategies
In May 2023, SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. The acquisition of bentracimab marks a significant step in strategy to grow through investment in innovative, biologic products for critical care conditions and leverages existing commercial and technical capabilities.
In January 2020, CytoSorbents Corporation, a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb® is now approved and immediately available for the removal of the anti-platelet agent, ticagrelor, during surgery requiring cardiopulmonary bypass (CPB), with the achievement of European Union regulatory approval and CE Mark label expansion for this indication.


Key Target Audience
Supplier, Manufacturer, Research organization, Government Regulatory, End-User Industry and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Acute Coronary Syndromes
  • Percutaneous Coronary Intervention
  • Others
By Distribution Channel
  • Retail Pharmacies
  • Hospitals and Healthcare Facilities
  • Specialty Pharmacies
  • Others

By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing prevalence of cardiovascular diseases, such as coronary artery disease and acute coronary syndrome
      • 3.2.2. The growing awareness of the benefits of ticagrelor in preventing heart attack and stroke
    • 3.3. Market Challenges
      • 3.3.1. Ticagrelor is a relatively expensive medication
      • 3.3.2. Ticagrelor faces competition from other antiplatelet medications.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ticagrelor, by Application, Distribution Channel, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Ticagrelor (Value)
      • 5.2.1. Global Ticagrelor by: Application (Value)
        • 5.2.1.1. Acute Coronary Syndromes
        • 5.2.1.2. Percutaneous Coronary Intervention
        • 5.2.1.3. Others
      • 5.2.2. Global Ticagrelor by: Distribution Channel (Value)
        • 5.2.2.1. Retail Pharmacies
        • 5.2.2.2. Hospitals and Healthcare Facilities
        • 5.2.2.3. Specialty Pharmacies
        • 5.2.2.4. Others
      • 5.2.3. Global Ticagrelor by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centers
        • 5.2.3.3. Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Ticagrelor Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Ticagrelor: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim International GmbH. (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Maithili Life Sciences Pvt. Ltd (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dr. Reddy’s Laboratories Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hisun Pharm Hangzhou (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Aarti Pharmalabs Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis International AG (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Cipla Limited (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Janssen Pharmaceuticals, Inc (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Ticagrelor Sale, by Application, Distribution Channel, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Ticagrelor (Value)
      • 7.2.1. Global Ticagrelor by: Application (Value)
        • 7.2.1.1. Acute Coronary Syndromes
        • 7.2.1.2. Percutaneous Coronary Intervention
        • 7.2.1.3. Others
      • 7.2.2. Global Ticagrelor by: Distribution Channel (Value)
        • 7.2.2.1. Retail Pharmacies
        • 7.2.2.2. Hospitals and Healthcare Facilities
        • 7.2.2.3. Specialty Pharmacies
        • 7.2.2.4. Others
      • 7.2.3. Global Ticagrelor by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centers
        • 7.2.3.3. Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Ticagrelor Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ticagrelor: by Application(USD Million)
  • Table 2. Ticagrelor Acute Coronary Syndromes , by Region USD Million (2018-2023)
  • Table 3. Ticagrelor Percutaneous Coronary Intervention , by Region USD Million (2018-2023)
  • Table 4. Ticagrelor Others , by Region USD Million (2018-2023)
  • Table 5. Ticagrelor: by Distribution Channel(USD Million)
  • Table 6. Ticagrelor Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 7. Ticagrelor Hospitals and Healthcare Facilities , by Region USD Million (2018-2023)
  • Table 8. Ticagrelor Specialty Pharmacies , by Region USD Million (2018-2023)
  • Table 9. Ticagrelor Others , by Region USD Million (2018-2023)
  • Table 10. Ticagrelor: by End User(USD Million)
  • Table 11. Ticagrelor Hospitals , by Region USD Million (2018-2023)
  • Table 12. Ticagrelor Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 13. Ticagrelor Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Ticagrelor Others , by Region USD Million (2018-2023)
  • Table 15. South America Ticagrelor, by Country USD Million (2018-2023)
  • Table 16. South America Ticagrelor, by Application USD Million (2018-2023)
  • Table 17. South America Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 18. South America Ticagrelor, by End User USD Million (2018-2023)
  • Table 19. Brazil Ticagrelor, by Application USD Million (2018-2023)
  • Table 20. Brazil Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 21. Brazil Ticagrelor, by End User USD Million (2018-2023)
  • Table 22. Argentina Ticagrelor, by Application USD Million (2018-2023)
  • Table 23. Argentina Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 24. Argentina Ticagrelor, by End User USD Million (2018-2023)
  • Table 25. Rest of South America Ticagrelor, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 27. Rest of South America Ticagrelor, by End User USD Million (2018-2023)
  • Table 28. Asia Pacific Ticagrelor, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Ticagrelor, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 31. Asia Pacific Ticagrelor, by End User USD Million (2018-2023)
  • Table 32. China Ticagrelor, by Application USD Million (2018-2023)
  • Table 33. China Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 34. China Ticagrelor, by End User USD Million (2018-2023)
  • Table 35. Japan Ticagrelor, by Application USD Million (2018-2023)
  • Table 36. Japan Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 37. Japan Ticagrelor, by End User USD Million (2018-2023)
  • Table 38. India Ticagrelor, by Application USD Million (2018-2023)
  • Table 39. India Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 40. India Ticagrelor, by End User USD Million (2018-2023)
  • Table 41. South Korea Ticagrelor, by Application USD Million (2018-2023)
  • Table 42. South Korea Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 43. South Korea Ticagrelor, by End User USD Million (2018-2023)
  • Table 44. Taiwan Ticagrelor, by Application USD Million (2018-2023)
  • Table 45. Taiwan Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 46. Taiwan Ticagrelor, by End User USD Million (2018-2023)
  • Table 47. Australia Ticagrelor, by Application USD Million (2018-2023)
  • Table 48. Australia Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 49. Australia Ticagrelor, by End User USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Ticagrelor, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Ticagrelor, by End User USD Million (2018-2023)
  • Table 53. Europe Ticagrelor, by Country USD Million (2018-2023)
  • Table 54. Europe Ticagrelor, by Application USD Million (2018-2023)
  • Table 55. Europe Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 56. Europe Ticagrelor, by End User USD Million (2018-2023)
  • Table 57. Germany Ticagrelor, by Application USD Million (2018-2023)
  • Table 58. Germany Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 59. Germany Ticagrelor, by End User USD Million (2018-2023)
  • Table 60. France Ticagrelor, by Application USD Million (2018-2023)
  • Table 61. France Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 62. France Ticagrelor, by End User USD Million (2018-2023)
  • Table 63. Italy Ticagrelor, by Application USD Million (2018-2023)
  • Table 64. Italy Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 65. Italy Ticagrelor, by End User USD Million (2018-2023)
  • Table 66. United Kingdom Ticagrelor, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 68. United Kingdom Ticagrelor, by End User USD Million (2018-2023)
  • Table 69. Netherlands Ticagrelor, by Application USD Million (2018-2023)
  • Table 70. Netherlands Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 71. Netherlands Ticagrelor, by End User USD Million (2018-2023)
  • Table 72. Rest of Europe Ticagrelor, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 74. Rest of Europe Ticagrelor, by End User USD Million (2018-2023)
  • Table 75. MEA Ticagrelor, by Country USD Million (2018-2023)
  • Table 76. MEA Ticagrelor, by Application USD Million (2018-2023)
  • Table 77. MEA Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 78. MEA Ticagrelor, by End User USD Million (2018-2023)
  • Table 79. Middle East Ticagrelor, by Application USD Million (2018-2023)
  • Table 80. Middle East Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 81. Middle East Ticagrelor, by End User USD Million (2018-2023)
  • Table 82. Africa Ticagrelor, by Application USD Million (2018-2023)
  • Table 83. Africa Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 84. Africa Ticagrelor, by End User USD Million (2018-2023)
  • Table 85. North America Ticagrelor, by Country USD Million (2018-2023)
  • Table 86. North America Ticagrelor, by Application USD Million (2018-2023)
  • Table 87. North America Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 88. North America Ticagrelor, by End User USD Million (2018-2023)
  • Table 89. United States Ticagrelor, by Application USD Million (2018-2023)
  • Table 90. United States Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 91. United States Ticagrelor, by End User USD Million (2018-2023)
  • Table 92. Canada Ticagrelor, by Application USD Million (2018-2023)
  • Table 93. Canada Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 94. Canada Ticagrelor, by End User USD Million (2018-2023)
  • Table 95. Mexico Ticagrelor, by Application USD Million (2018-2023)
  • Table 96. Mexico Ticagrelor, by Distribution Channel USD Million (2018-2023)
  • Table 97. Mexico Ticagrelor, by End User USD Million (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Ticagrelor: by Application(USD Million)
  • Table 113. Ticagrelor Acute Coronary Syndromes , by Region USD Million (2025-2030)
  • Table 114. Ticagrelor Percutaneous Coronary Intervention , by Region USD Million (2025-2030)
  • Table 115. Ticagrelor Others , by Region USD Million (2025-2030)
  • Table 116. Ticagrelor: by Distribution Channel(USD Million)
  • Table 117. Ticagrelor Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 118. Ticagrelor Hospitals and Healthcare Facilities , by Region USD Million (2025-2030)
  • Table 119. Ticagrelor Specialty Pharmacies , by Region USD Million (2025-2030)
  • Table 120. Ticagrelor Others , by Region USD Million (2025-2030)
  • Table 121. Ticagrelor: by End User(USD Million)
  • Table 122. Ticagrelor Hospitals , by Region USD Million (2025-2030)
  • Table 123. Ticagrelor Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 124. Ticagrelor Pharmacies , by Region USD Million (2025-2030)
  • Table 125. Ticagrelor Others , by Region USD Million (2025-2030)
  • Table 126. South America Ticagrelor, by Country USD Million (2025-2030)
  • Table 127. South America Ticagrelor, by Application USD Million (2025-2030)
  • Table 128. South America Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 129. South America Ticagrelor, by End User USD Million (2025-2030)
  • Table 130. Brazil Ticagrelor, by Application USD Million (2025-2030)
  • Table 131. Brazil Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 132. Brazil Ticagrelor, by End User USD Million (2025-2030)
  • Table 133. Argentina Ticagrelor, by Application USD Million (2025-2030)
  • Table 134. Argentina Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 135. Argentina Ticagrelor, by End User USD Million (2025-2030)
  • Table 136. Rest of South America Ticagrelor, by Application USD Million (2025-2030)
  • Table 137. Rest of South America Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 138. Rest of South America Ticagrelor, by End User USD Million (2025-2030)
  • Table 139. Asia Pacific Ticagrelor, by Country USD Million (2025-2030)
  • Table 140. Asia Pacific Ticagrelor, by Application USD Million (2025-2030)
  • Table 141. Asia Pacific Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 142. Asia Pacific Ticagrelor, by End User USD Million (2025-2030)
  • Table 143. China Ticagrelor, by Application USD Million (2025-2030)
  • Table 144. China Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 145. China Ticagrelor, by End User USD Million (2025-2030)
  • Table 146. Japan Ticagrelor, by Application USD Million (2025-2030)
  • Table 147. Japan Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 148. Japan Ticagrelor, by End User USD Million (2025-2030)
  • Table 149. India Ticagrelor, by Application USD Million (2025-2030)
  • Table 150. India Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 151. India Ticagrelor, by End User USD Million (2025-2030)
  • Table 152. South Korea Ticagrelor, by Application USD Million (2025-2030)
  • Table 153. South Korea Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 154. South Korea Ticagrelor, by End User USD Million (2025-2030)
  • Table 155. Taiwan Ticagrelor, by Application USD Million (2025-2030)
  • Table 156. Taiwan Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 157. Taiwan Ticagrelor, by End User USD Million (2025-2030)
  • Table 158. Australia Ticagrelor, by Application USD Million (2025-2030)
  • Table 159. Australia Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 160. Australia Ticagrelor, by End User USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Ticagrelor, by Application USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Ticagrelor, by End User USD Million (2025-2030)
  • Table 164. Europe Ticagrelor, by Country USD Million (2025-2030)
  • Table 165. Europe Ticagrelor, by Application USD Million (2025-2030)
  • Table 166. Europe Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 167. Europe Ticagrelor, by End User USD Million (2025-2030)
  • Table 168. Germany Ticagrelor, by Application USD Million (2025-2030)
  • Table 169. Germany Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 170. Germany Ticagrelor, by End User USD Million (2025-2030)
  • Table 171. France Ticagrelor, by Application USD Million (2025-2030)
  • Table 172. France Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 173. France Ticagrelor, by End User USD Million (2025-2030)
  • Table 174. Italy Ticagrelor, by Application USD Million (2025-2030)
  • Table 175. Italy Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 176. Italy Ticagrelor, by End User USD Million (2025-2030)
  • Table 177. United Kingdom Ticagrelor, by Application USD Million (2025-2030)
  • Table 178. United Kingdom Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 179. United Kingdom Ticagrelor, by End User USD Million (2025-2030)
  • Table 180. Netherlands Ticagrelor, by Application USD Million (2025-2030)
  • Table 181. Netherlands Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 182. Netherlands Ticagrelor, by End User USD Million (2025-2030)
  • Table 183. Rest of Europe Ticagrelor, by Application USD Million (2025-2030)
  • Table 184. Rest of Europe Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 185. Rest of Europe Ticagrelor, by End User USD Million (2025-2030)
  • Table 186. MEA Ticagrelor, by Country USD Million (2025-2030)
  • Table 187. MEA Ticagrelor, by Application USD Million (2025-2030)
  • Table 188. MEA Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 189. MEA Ticagrelor, by End User USD Million (2025-2030)
  • Table 190. Middle East Ticagrelor, by Application USD Million (2025-2030)
  • Table 191. Middle East Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 192. Middle East Ticagrelor, by End User USD Million (2025-2030)
  • Table 193. Africa Ticagrelor, by Application USD Million (2025-2030)
  • Table 194. Africa Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 195. Africa Ticagrelor, by End User USD Million (2025-2030)
  • Table 196. North America Ticagrelor, by Country USD Million (2025-2030)
  • Table 197. North America Ticagrelor, by Application USD Million (2025-2030)
  • Table 198. North America Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 199. North America Ticagrelor, by End User USD Million (2025-2030)
  • Table 200. United States Ticagrelor, by Application USD Million (2025-2030)
  • Table 201. United States Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 202. United States Ticagrelor, by End User USD Million (2025-2030)
  • Table 203. Canada Ticagrelor, by Application USD Million (2025-2030)
  • Table 204. Canada Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 205. Canada Ticagrelor, by End User USD Million (2025-2030)
  • Table 206. Mexico Ticagrelor, by Application USD Million (2025-2030)
  • Table 207. Mexico Ticagrelor, by Distribution Channel USD Million (2025-2030)
  • Table 208. Mexico Ticagrelor, by End User USD Million (2025-2030)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ticagrelor: by Application USD Million (2018-2023)
  • Figure 5. Global Ticagrelor: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Ticagrelor: by End User USD Million (2018-2023)
  • Figure 7. South America Ticagrelor Share (%), by Country
  • Figure 8. Asia Pacific Ticagrelor Share (%), by Country
  • Figure 9. Europe Ticagrelor Share (%), by Country
  • Figure 10. MEA Ticagrelor Share (%), by Country
  • Figure 11. North America Ticagrelor Share (%), by Country
  • Figure 12. Global Ticagrelor share by Players 2023 (%)
  • Figure 13. Global Ticagrelor share by Players (Top 3) 2023(%)
  • Figure 14. Global Ticagrelor share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 21. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 22. Boehringer Ingelheim International GmbH. (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Boehringer Ingelheim International GmbH. (Germany) Revenue: by Geography 2023
  • Figure 24. Maithili Life Sciences Pvt. Ltd (India) Revenue, Net Income and Gross profit
  • Figure 25. Maithili Life Sciences Pvt. Ltd (India) Revenue: by Geography 2023
  • Figure 26. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 27. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2023
  • Figure 28. Dr. Reddy’s Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 29. Dr. Reddy’s Laboratories Ltd. (India) Revenue: by Geography 2023
  • Figure 30. Hisun Pharm Hangzhou (China) Revenue, Net Income and Gross profit
  • Figure 31. Hisun Pharm Hangzhou (China) Revenue: by Geography 2023
  • Figure 32. Aarti Pharmalabs Limited (India) Revenue, Net Income and Gross profit
  • Figure 33. Aarti Pharmalabs Limited (India) Revenue: by Geography 2023
  • Figure 34. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 36. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 38. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 40. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 41. Cipla Limited (India) Revenue: by Geography 2023
  • Figure 42. Janssen Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 43. Janssen Pharmaceuticals, Inc (United States) Revenue: by Geography 2023
  • Figure 44. Global Ticagrelor: by Application USD Million (2025-2030)
  • Figure 45. Global Ticagrelor: by Distribution Channel USD Million (2025-2030)
  • Figure 46. Global Ticagrelor: by End User USD Million (2025-2030)
  • Figure 47. South America Ticagrelor Share (%), by Country
  • Figure 48. Asia Pacific Ticagrelor Share (%), by Country
  • Figure 49. Europe Ticagrelor Share (%), by Country
  • Figure 50. MEA Ticagrelor Share (%), by Country
  • Figure 51. North America Ticagrelor Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Pfizer Inc. (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Maithili Life Sciences Pvt. Ltd (India)
  • Teva Pharmaceutical Industries (Israel)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Hisun Pharm Hangzhou (China)
  • Aarti Pharmalabs Limited (India)
  • Bristol-Myers Squibb Company (United States)
  • Novartis International AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Cipla Limited (India)
  • Janssen Pharmaceuticals, Inc (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 239 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ticagrelor Market Quantitative research analysis
Global Ticagrelor Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (United Kingdom), Pfizer Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Boehringer Ingelheim International GmbH. (Germany), Maithili Life Sciences Pvt. Ltd (India), Teva Pharmaceutical Industries (Israel), Dr. Reddy’s Laboratories Ltd. (India), Hisun Pharm Hangzhou (China), Aarti Pharmalabs Limited (India), Bristol-Myers Squibb Company (United States), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Cipla Limited (India) and Janssen Pharmaceuticals, Inc (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Ticagrelor Market during projected period 2023-2030.
The Ticagrelor market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Ticagrelor Market Report?

Have a Query? Click Here

Other Related Reports

Intravenous (IV) Solution Comprehensive Study by Type (Saline, Dextran, Lactated Ringers, Amino Acids), Application (Hospitals & Clinics, Ambulatory, Homecare), Nutrition Type (Carbohydrates, Salts a...
$ 3800
Arnica Montana Comprehensive Study by Type (Arnica Ointment, Arnica Orally), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Sales Channel (Direct, E-commerce), Source Type ...
$ 3350
Veterinary Electrosurgery Comprehensive Study by Type (Monopolar Electrosurgery, Bipolar Electrosurgery, Consumables & Accessories), Application (General Surgery, Ophthalmic Surgery, Orthopedic Surge...
$ 3650
Continence Care Comprehensive Study by Type (Urinary Continence Care, Fecal Continence Care), Application (Spinal Cord Injury, Benign Prostate Hyperplasia, Others), Product Type (Intermittent Cathete...
$ 3650
Topical Steroids Comprehensive Study by Application (Hospitals, Dermatology Clinics, Pharmacies), By Treatment (Dermatitis, Insect stings, Eczema, Psoriasis, Others), By Potency Class (Low, Moderate,...
$ 3450
Anaplastic Thyroid Cancer Treatment Comprehensive Study by Application (Hospital, Drugs Store, Others), Treatments (Surgical Treatments, Radiation Therapy, Novel Therapy, Others), Methods (Oral, Inje...
$ 3800